Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2A | P28223 | 8/20 | 0.47 |
| ▸ | HTR1A | P08908 | 2/20 | 0.47 |
| ▸ | HTR7 | P34969 | 3/20 | 0.45 |
| ▸ | DRD2 | P14416 | 5/20 | 0.44 |
| ▸ | HTR6 | P50406 | 1/20 | 0.44 |
| ▸ | ABCC1 | P33527 | 7/20 | 0.42 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | HPGD | P15428 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.40 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6220537 | 0.93 | HTR2A (0.51) | HTR2AHTR1AHTR7DRD2HTR6 | |
| SCHEMBL6748889 | 0.90 | ABCC1 (0.41) | HTR2AHTR1AHTR7DRD2HTR6 | |
| SCHEMBL6220399 | 0.88 | HTR2A (0.51) | HTR2AHTR1AHTR7DRD2HTR6 | |
| Hydrochloric Acid SCHEMBL6750990 | 0.88 | HTR2A (0.50) | HTR2AHTR1AHTR7DRD2HTR6 | |
| SCHEMBL6743912 | 0.83 | HTR1A (0.53) | HTR2AHTR1AHTR7DRD2HTR6 | |
| SCHEMBL6223321 | 0.82 | HTR1A (0.51) | HTR2AHTR1AHTR7DRD2HTR6 | |
| SCHEMBL6746149 | 0.79 | DRD2 (0.59) | HTR2AHTR1AHTR7DRD2HTR6 | |
| SCHEMBL6747869 | 0.76 | PARP1 (0.49) | HTR2AHTR1AHTR7DRD2ABCC1 | |
| SCHEMBL6747864 | 0.75 | HTR1A (0.44) | HTR2AHTR1AHTR7DRD2ABCC1 | |
| SCHEMBL6220906 | 0.75 | HTR1A (0.62) | HTR2AHTR1AHTR7DRD2HTR6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040138230-A1 | Heterocyclic substituted piperazines for the treatment of schizophrenia | ANDREANA TONJA LYNN (US) | 2004-07-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040138230-A1 | Heterocyclic substituted piperazines for the treatment of schizophrenia | CNR1, DRD2, CNR2 | HTR2A 16/4885HTR1A 17/4885HTR7 119/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.